Gluten Challenge Induces Skin and Small Bowel Relapse in Long-Term Gluten-Free Diet-Treated Dermatitis Herpetiformis.
Adult
Aged
Biopsy, Needle
Cohort Studies
Dermatitis Herpetiformis
/ diet therapy
Diet, Gluten-Free
/ methods
Female
Finland
Follow-Up Studies
Humans
Immunoglobulin A
/ immunology
Immunohistochemistry
Intestinal Mucosa
/ pathology
Intestine, Small
/ pathology
Male
Middle Aged
Patient Safety
Prospective Studies
Risk Assessment
Statistics, Nonparametric
Time Factors
Treatment Outcome
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
14
12
2018
revised:
11
03
2019
accepted:
25
03
2019
pubmed:
19
4
2019
medline:
4
6
2020
entrez:
19
4
2019
Statut:
ppublish
Résumé
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of celiac disease causing an itchy, blistering rash. Granular IgA deposits in the skin are pathognomonic for DH, and the treatment of choice is a lifelong gluten-free diet (GFD). Preliminary evidence suggests that there are patients with DH who redevelop gluten tolerance after adherence to a GFD treatment. To evaluate this, we performed a 12-month gluten challenge with skin and small-bowel mucosal biopsy samples in 19 patients with DH who had adhered to a GFD for a mean of 23 years. Prechallenge biopsy was negative for skin IgA and transglutaminase 3 deposits in 16 patients (84%) and indicated normal villous height-to-crypt depth ratios in the small bowel mucosa in all 19 patients. The gluten challenge caused a relapse of the rash in 15 patients (79%) in a mean of 5.6 months; of these 15 patients, 13 had skin IgA and transglutaminase 3 deposits, and 12 had small-bowel villous atrophy. In addition, three patients without rash or immune deposits in the skin developed villous atrophy, whereas one patient persisted without any signs of relapse. In conclusion, 95% of the patients with DH were unable to tolerate gluten even after long-term adherence to a GFD. Therefore, lifelong GFD treatment remains justified in all patients with DH.
Identifiants
pubmed: 30998982
pii: S0022-202X(19)31485-X
doi: 10.1016/j.jid.2019.03.1150
pii:
doi:
Substances chimiques
Immunoglobulin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2108-2114Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.